Health Care·Biotechnology·$8.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.22 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.22 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the ongoing challenges but emphasized their commitment to long-term strategies. They did not provide detailed commentary on revenue or future expectations.
Management did not provide specific insights into revenue performance.
The company is focusing on long-term growth despite current challenges.
The earnings report indicates that Krystal Biotech Inc is still facing challenges, particularly reflected in the negative EPS. The stock reaction of a 6.66% decline suggests investor concern over the lack of revenue information and guidance. Without clear direction from management, investors may remain cautious about the company's short-term outlook.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SEMPRA
Aug 2, 2019